C. Diff Mortality Rates by Age: A Statistical Breakdown

Age is the single strongest demographic predictor of death from Clostridioides difficile infection (commonly called C. diff). Adults over 65 face substantially higher mortality than younger patients, and the risk keeps climbing with each additional decade of life. A study of hospitalized elderly patients found excess mortality of roughly 26% at 30 days and over 41% at six months following C. diff diagnosis, figures that dwarf the single-digit mortality rates typical among younger adults.¹ But the relationship between age and C. diff death is more layered than a simple “older equals worse,” with recurrence, immune decline, care setting, and even how the infection is diagnosed all shaping who survives and who does not.

Mortality in Older Adults, by the Numbers

The two strongest risk factors for developing C. diff in the first place are antibiotic exposure and being over 65.² Once infected, older adults are also far more likely to die. In one district hospital study, the excess mortality attributable to C. diff in elderly inpatients was about 12% at seven days, jumped to 26% by 30 days, hit 38% at 90 days, and climbed to over 41% at six months.¹ Those numbers reflect a sustained mortality burden that continues well beyond the acute illness. The infection either contributes directly to long-term decline or serves as a marker that a patient was already on a dangerous trajectory, and the research suggests both mechanisms are at work.

At a national level, U.S. data from 1999 to 2023 show that the age-adjusted mortality rate for C. diff-related deaths rose from 0.72 to 2.17 per 100,000, with a peak of 4.78 during the worst years of the epidemic.³ The good news is that in-hospital mortality from C. diff began declining around 2008, and the proportion of patients aged 65 and older among those dying also decreased over roughly a decade.⁴ Improved antibiotic stewardship programs, infection-control measures, and a decline in the most virulent strain circulating in hospitals all likely contributed to that shift. Still, older adults remain the highest-risk group by a wide margin.

Why Older Immune Systems Lose the Fight

The reason age dominates the mortality picture is partly immunological. Research comparing immune cells from healthy elderly donors to those from younger donors found that neutrophils from older individuals were substantially worse at engulfing and destroying C. diff bacteria. Intriguingly, when those same elderly neutrophils were placed in serum from young donors, the phagocytosis defect nearly reversed, suggesting that the problem lies not just in the immune cells themselves but also in age-related changes to blood proteins that help flag bacteria for destruction.⁵ This kind of two-pronged immunological erosion means the body’s first line of defense against C. diff weakens on multiple fronts simultaneously as people age.

Beyond the immune system itself, older adults carry a heavier load of chronic diseases. The very elderly (typically defined as those over 80) have significantly higher comorbidity burdens than younger C. diff patients.⁶ Kidney disease, heart failure, diabetes, and malnutrition all reduce the body’s ability to tolerate the dehydration and systemic inflammation that C. diff triggers. Yet comorbidity alone does not explain the mortality gap. A large population-based study found that C. diff infection was associated with a sixfold increase in death rates compared to matched controls, and the mortality increase was actually most pronounced in people who had no chronic comorbidities at all.⁷ The infection itself is lethal enough that even a relatively healthy older person can be killed by it.

Recurrence Is Where the Deaths Pile Up

One of the most dangerous aspects of C. diff is its tendency to come back after treatment. And recurrence is where age-related mortality spikes dramatically. Among older adults, the death rate after a recurrent episode was almost ten times higher than after a first episode, roughly 25% versus under 3%.⁸ A separate study of older inpatients found that patients who experienced recurrence had about two and a half times the risk of death compared to those whose infection stayed resolved after the first course of treatment.⁹

This makes clinical sense: each round of C. diff further depletes the gut’s protective microbial community, making the next relapse more likely and harder to treat. It also means that the most important interventions in older adults are those that prevent recurrence. Treating the first episode effectively matters, but preventing the second episode may matter more for survival.

Children and Younger Adults

The picture looks completely different at the other end of the age spectrum. Infants, somewhat surprisingly, carry C. diff in their intestines at very high rates, over 40% in the first year of life, but rarely get sick from it. Colonization peaks between six and twelve months, stays around 22% in toddlers, and then gradually drops to the 1–3% carriage rates seen in healthy adults.¹⁰ When children do develop actual C. diff disease, severe outcomes are uncommon, with up to about 8% developing severe infection.¹⁰ Deaths from C. diff in the pediatric population are rare enough that most studies focus exclusively on adult cohorts.

For working-age adults between 18 and 64, C. diff is far less lethal than in the elderly, but it is not trivial. Healthcare costs within two months of a C. diff diagnosis averaged about $18,400 for patients aged 50 to 64, compared to roughly $12,000 for those aged 18 to 49, both far exceeding the costs of matched patients without the infection.¹¹ The financial burden climbs with age even within the under-65 group, and healthcare-associated infections generally cost more than community-acquired ones. While mortality in this age bracket is far lower than in the elderly, C. diff still extracts a meaningful toll in hospitalizations, lost work, and out-of-pocket costs.

Where You Get Infected Changes Your Odds

The setting in which a person contracts C. diff independently influences mortality, and this is tightly connected to age because older adults are more likely to be in higher-risk environments. Patients admitted to the hospital from skilled nursing facilities had a mortality rate of about 13.5%, compared to roughly 8% for patients arriving from other settings.¹² Nursing facility residents also had higher readmission rates, longer hospital stays, and greater costs. This reflects both the frailer baseline health of skilled nursing residents and the fact that long-term care environments, with their frequent antibiotic use and close-quarter living, create ideal conditions for C. diff transmission.

A finding that complicates the standard age-equals-worse narrative comes from research on racial and ethnic disparities. At one Southern California academic hospital, patients from racial and ethnic minority groups diagnosed with C. diff had a median age about ten years younger than their non-minority counterparts, yet were more likely to require ICU admission and to have prolonged hospitalizations.¹³ That finding runs against the established understanding that older age drives worse outcomes, and it suggests that social determinants of health, access to care, and underlying health inequities can overwhelm the age-based risk profile in specific populations.

Treatment Outcomes in Older Patients

The standard first-line antibiotics for C. diff are vancomycin and fidaxomicin, and the choice between them increasingly favors fidaxomicin for older patients. A meta-analysis found no significant difference in short-term mortality between the two drugs, but fidaxomicin showed a clear advantage in all-cause mortality beyond 60 days, reducing the risk by about 40% compared to vancomycin.¹⁴ That long-tail mortality benefit matters most in exactly the patients who need it: older adults who face months of elevated death risk after their initial episode.

A trial specifically enrolling patients aged 60 and older compared an extended-pulsed course of fidaxomicin to standard vancomycin and found that about 70% of fidaxomicin patients achieved sustained cure at 30 days after treatment ended, versus 59% on vancomycin.¹⁵ The safety profiles were similar. That sustained-cure gap is meaningful because, as noted earlier, recurrence is where most age-related C. diff deaths occur.

For patients who keep relapsing despite antibiotics, fecal microbiota transplantation (FMT) has become an important option. In a study of 146 elderly patients with recurrent, severe, or complicated C. diff, FMT achieved a primary cure rate of about 83% and an overall cure rate of roughly 96% when repeat procedures were included.¹⁶ Serious side effects were uncommon, though not absent. A larger real-world study, in which the median patient age was 73, found a 76% cure rate after the first FMT treatment and a 79% overall cure rate after repeated treatments, with a 90-day mortality of about 10%.¹⁷ That 10% mortality rate reflects the reality that many patients receiving FMT are already severely ill, often with fulminant disease or multiple prior relapses.

Proton Pump Inhibitors and a Surprising Contradiction

Proton pump inhibitors (PPIs), the widely used acid-reducing medications like omeprazole and pantoprazole, have a complicated relationship with C. diff outcomes. PPIs are a known risk factor for developing C. diff in the first place, because suppressing stomach acid makes it easier for ingested spores to survive and reach the colon. But the data on whether PPIs worsen mortality after a patient already has C. diff are unexpectedly muddled. One study of elderly C. diff patients found that PPI exposure was actually associated with a 55% reduction in 180-day mortality, a finding the authors attributed to possible confounding rather than a protective effect of the drug itself.¹⁸

Complicating things further, another study found that PPIs increased the combined risk of recurrence or death in men with C. diff, roughly doubling the hazard, but had no such effect in women.¹⁹ These contradictory findings illustrate how difficult it is to untangle the contributions of individual medications in elderly patients who are typically on multiple drugs simultaneously. The practical takeaway is that clinicians should reassess whether a PPI is still necessary in a patient with active C. diff, but blanket discontinuation is not clearly supported either.

When Surgery Becomes the Only Option

At the extreme end of severity, fulminant C. diff colitis sometimes requires emergency removal of part or all of the colon. This is uncommon but carries staggering mortality at any age. One study reported an overall 30-day mortality after emergency colectomy for C. diff of 37%, with age as an independent risk factor: each additional year of life slightly but significantly increased the odds of dying.²⁰ Other risk factors for death after surgery included extremely high white blood cell counts, elevated blood lactate levels, and very low albumin, all markers of severe systemic illness. A separate analysis confirmed that colectomy for C. diff colitis carries substantial mortality regardless of patient age, though older patients fared worse on average.²¹

The decision to operate is almost always a last resort. Patients who reach this point have typically failed antibiotic therapy and developed complications such as toxic megacolon, bowel perforation, or septic shock. The high surgical mortality reflects the severity of the disease at that stage rather than the surgery itself being inherently dangerous. For older adults, the threshold for considering surgery is particularly fraught, because the very factors that make them sicker from C. diff, a weakened immune system, frailty, and multiple comorbidities, also make them worse surgical candidates.

The Overdiagnosis Problem and How It Skews the Numbers

One often-overlooked factor in any discussion of C. diff mortality statistics is the possibility that not every positive test result represents true disease. Modern molecular tests (PCR) are extremely sensitive and can detect C. diff DNA in stool even when the organism is not actively producing the toxins that cause illness. A study of over 1,400 hospitalized adults found that while 21% tested positive by PCR, fewer than half of those positives had detectable toxin in their stool.²² The patients who were PCR-positive but toxin-negative had significantly less diarrhea, less intestinal inflammation, and no C. diff-related complications, whereas toxin-positive patients experienced a complication rate of nearly 8% and a C. diff-related death rate of over 8%.²²

This matters for interpreting age-based mortality rates because elderly patients are tested for C. diff more often (they are in the hospital more often and receive more antibiotics), and a sensitive test may label some of them as C. diff cases when they are actually just carriers. If these mild or non-disease cases are included in the denominator when calculating mortality rates, they could dilute the apparent death rate. Conversely, if only toxin-confirmed cases are counted, the mortality rate for elderly patients looks even more alarming. The testing method used at a given hospital therefore shapes the reported numbers, and comparing mortality rates across institutions or time periods requires knowing which diagnostic approach was in use.

Hypervirulent Strains and Age-Specific Lethality

Not all C. diff strains are equally dangerous. The NAP1/BI/027 strain, which drove the epidemic spikes of the 2000s and early 2010s, produces higher levels of toxins and sporulates more aggressively than most other C. diff lineages. When this strain circulated widely, it was associated with death rates about 50% higher than other strains. The lethality was not evenly distributed: patients aged 75 to 84 infected with NAP1 had an especially high mortality rate, approaching one in five. As antibiotic stewardship programs improved and the prevalence of NAP1 declined in many hospitals, overall C. diff mortality began falling as well, which partly explains the downward trends observed in national data from around 2008 onward.⁴ This is a reminder that the age-mortality relationship in C. diff is not purely biological: it also depends on which strains are circulating at any given time, and older adults are disproportionately vulnerable to the worst ones.